Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H1 2018

  • ID: 4457549
  • Report
  • 97 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Celldex Therapeutics Inc
  • Etubics Corp
  • GlaxoSmithKline Plc
  • MediaPharma SRL
  • Novartis AG
  • MORE
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H1 2018

Summary

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Receptor tyrosine-protein kinase erbB-3 or HER3 is a membrane bound protein encoded by the ERBB3 gene. It belongs to tyrosine-protein kinase family. It plays an essential role as cell surface receptor for neuregulins. It binds to neuregulin-1 (NRG1) and is activated by it. It also activated by CSPG5.

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) pipeline Target constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 8, 4, 2, 6 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Solid Tumor, Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Breast Cancer, Esophageal Cancer, Lung Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Hepatocellular Carcinoma, Lung Adenocarcinoma, Metastatic Colorectal Cancer, Pancreatic Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Colorectal Tumor, Endometrial Cancer, Epithelial Tumor, Ewing Sarcoma, Head And Neck Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Malignant Mesothelioma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Pancreatic Cancer, Nasopharyngeal Cancer, Neuroendocrine Tumors, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Osteosarcoma, Pancreatic Tumor, Peritoneal Tumor, Skin Cancer, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer and Thyroid Cancer.

The latest report Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H1 2018, outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)
  • The report reviews Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Celldex Therapeutics Inc
  • Etubics Corp
  • GlaxoSmithKline Plc
  • MediaPharma SRL
  • Novartis AG
  • MORE
Introduction

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Overview

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Celldex Therapeutics Inc

Daiichi Sankyo Co Ltd

Etubics Corp

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Hanmi Pharmaceuticals Co Ltd

Hummingbird Bioscience Pte Ltd

ImmunoGen Inc

MediaPharma SRL

Merrimack Pharmaceuticals Inc

Merus NV

Novartis AG

Shanghai Fosun Pharmaceutical (Group) Co Ltd

Sorrento Therapeutics Inc

Symphogen A/S

Takis Srl

XuanZhu Pharma Co Ltd

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Drug Profiles

AV-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BA-0702 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDX-3379 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elgemtumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETBX-031 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FCN-411 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2849330 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMBD-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

huHER3-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

istiratumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-5209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lumretuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MCLA-125 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MPEV-201959 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

patritumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poziotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sapitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seribantumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit EGFR, HER2 and HER3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sym-013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TK-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XZP-5491 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Dormant Products

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Discontinued Products

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Dec 21, 2017: CANbridge Life Sciences Submits Investigational New Drug Application for CAN017 Trial in Esophageal Squamous Cell Cancer (ESCC) In China

Nov 17, 2017: Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma

Oct 30, 2017: Merrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung Cancer

Oct 30, 2017: Spectrum Pharmaceuticals Announces Initiation of a Multicenter Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer (NSCLC) Patients with Exon 20 Insertion Mutation in EGFR or HER2

Oct 17, 2017: Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan

Sep 28, 2017: Spectrum Pharmaceuticals Highlights Poziotinib Data in Lung Cancer to be Presented in an Oral Presentation at the 18th IASLC World Conference on Lung Cancer in Yokohama, Japan, October 15-18,

Sep 13, 2017: AVEO Oncology Announces Receipt of $0.5 million Payment from CANbridge

Jun 19, 2017: Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of

Apr 03, 2017: AVEO Announces Milestone Payment from CANbridge for AV-203

Apr 03, 2017: Hummingbird Bioscience presents update on HMBD-001 at AACR in Washington DC

Mar 30, 2017: Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations

Mar 27, 2017: Merrimack to Present Data on Istiratumab (MM-141) at the 2017 American Association for Cancer Research Annual Meeting

Dec 08, 2016: Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung Cancer

Dec 05, 2016: Spectrum Pharmaceuticals Presents Abstract on Poziotinib at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10,

Nov 17, 2016: Spectrum Pharmaceuticals Announces Poziotinib Data Presentation at the 17th IASLC World Conference on Lung Cancer in Vienna, Austria, December 4-7,

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1

Number of Products under Development by Therapy Areas, H1

Number of Products under Development by Indications, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Number of Products under Investigation by Universities/Institutes, H1

Products under Investigation by Universities/Institutes, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Pipeline by AstraZeneca Plc, H1

Pipeline by AVEO Pharmaceuticals Inc, H1

Pipeline by Celldex Therapeutics Inc, H1

Pipeline by Daiichi Sankyo Co Ltd, H1

Pipeline by Etubics Corp, H1

Pipeline by F. Hoffmann-La Roche Ltd, H1

Pipeline by GlaxoSmithKline Plc, H1

Pipeline by Hanmi Pharmaceuticals Co Ltd, H1

Pipeline by Hummingbird Bioscience Pte Ltd, H1

Pipeline by ImmunoGen Inc, H1

Pipeline by MediaPharma SRL, H1

Pipeline by Merrimack Pharmaceuticals Inc, H1

Pipeline by Merus NV, H1

Pipeline by Novartis AG, H1

Pipeline by Shanghai Fosun Pharmaceutical (Group) Co Ltd, H1

Pipeline by Sorrento Therapeutics Inc, H1

Pipeline by Symphogen A/S, H1

Pipeline by Takis Srl, H1

Pipeline by XuanZhu Pharma Co Ltd, H1

Dormant Products, H1

Discontinued Products, H1

List of Figures

Number of Products under Development by Stage of Development, H1

Number of Products under Development by Top 10 Indications, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AstraZeneca Plc
  • AVEO Pharmaceuticals Inc
  • Celldex Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Etubics Corp
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Hanmi Pharmaceuticals Co Ltd
  • Hummingbird Bioscience Pte Ltd
  • ImmunoGen Inc
  • MediaPharma SRL
  • Merrimack Pharmaceuticals Inc
  • Merus NV
  • Novartis AG
  • Shanghai Fosun Pharmaceutical (Group) Co Ltd
  • Sorrento Therapeutics Inc
  • Symphogen A/S
  • Takis Srl
  • XuanZhu Pharma Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll